Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients with Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome with FLT3-ITD Mutation
The goal of this clinical research study is to learn if 5-azacitidine and sorafenib can help to control the disease in patients with AML and high risk MDS with FLT3-ITD mutation. The safety of this drug combination will also be studied.
Disease Group: Leukemia
Treatment Agent: 5-Azacytidine,Sorafenib
Treatment Location: Only at MD Anderson
Sponsor: Bayer HealthCare Pharmaceuticals Inc.
IRB Review and Approval Date: 02/06/2015
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: